Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• IL1RA derived peptides for treatment of diabetic nephropathy
• the present disclosure relates to peptides derived from IL-1R antagonist protein (IL1 RA) for treatment of diabetic nephropathy.
• IL1 RA IL-1R antagonist protein
• Interleukin 1 is a general name for two distinct pro-inflammatory cytokines proteins, IL-1 alpha and IL-1 beta. IL-1 exerts its effects by binding to specific transmembrane receptors (IL-1R) on multiple cell types. The effects of IL-1 are counteracted by natural inhibitors such as soluble IL-1 receptors and IL-1 R antagonist protein (IL1RA). IL1RA inhibits the effect of IL-1 by blocking its interaction with the cell surface receptors.
• IL-1R transmembrane receptors
• IL1RA IL-1 R antagonist protein
• Therapeutic approaches for targeting IL-1 for anti-inflammatory purposes have been addressed in the art. These include administration of recombinant IL-1R antagonist protein, IL-1 trap fusion proteins, anti-IL-1 antibodies, anti-IL-1 Rl and soluble IL-1RI and II in experimental models of arthritis (reviewed in Gabay C et al. 2010).
• Anakinra (US5075222) is a recombinantly produced protein that contains the N- terminal, methionylated, nonglycosylated version of human IL-1RA, which blocks the actions of IL-1 without any detectable agonist activity.
• Anakinra has been tested for the treatment of rheumatoid arthritis, adult-onset Still’s disease, systemic onset juvenile idiopathic arthritis, osteoarthritis and type 2 diabetes mellitus.
• Anakinra is approved for treatment of rheumatoid arthritis; it is delivered as an injection concentrate with 100 mg in each dose; it is prepared from genetically modified E. coli using recombinant DNA technology; and it has a high molecular weight.
• WO 2012/122985 and WO 2017/063657 discloses a 10-amino acid peptide derived from of I LIRA: SGRKSSKMQA (SEQ ID NO: 1), and its use in treating various disorders.
• SEQ ID NO:1 has previously been shown to inhibit interleukin Ib-induced NF-kB signaling and macrophage secretion of TNFa, and hence is a potent inhibitor of inflammatory responses (Klementiev 2014).
• Diabetic kidney disease (DKD) also known as diabetic nephropathy, has not historically been considered as an immune-mediated disease as metabolic and haemodynamic factors have been thought to be the main causes of the renal injuries.
• the progressive non-infectious inflammation involves glomerular and tubular cells resulting in gradual loss of kidney function.
• the blood glucose and blood pressure shall be kept as normal as possible which will delay loss of kidney function.
• no specific treatment of this innate inflammation is developed and the declining glomerular filtration and tubular function does not stop, and loss of renal function continue.
• the treatment will be chronic dialysis and in some cases kidney transplantation.
• interventions that prevent or halt the predestined inflammatory induced decline in all functions of nephrons focus on inhibition of the renal inflammation is needed.
• Urine albumin is often measured in spot urine and corrected for creatinine in the same urine sample, ACR mg/g.
• the ACR are divided in three groups, normo-albuminuria ACR ⁇
• Urine albumin and Kidney Injury Molecule-1 are both biomarkers of kidney innate inflammation as seen in various autoimmune diseases which involve the kidneys as well as in other non-autoimmune diseases (Coca 2017, Cai 2019, Levey 2019).
• Human renal biopsies have confirmed the presence of inflammatory cells in both glomeruli, the tubuli and the interstitium at all stages of diabetic nephropathy (Kahn 2019, Calle 2021). Summary
• peptides derived from I LIRA significantly reduce urinary albumin corrected for creatinine (ACR) and the kidney- injuring molecule corrected for creatinine (KIM-1/CR).
• Urine albumin and KIM-1 are both biomarkers of kidney innate inflammation as seen in various diseases which involve the kidneys, including diabetic nephropathy.
• diabetic nephropathy has not historically been considered as an immune-mediated disease, there is a need for compounds and medicaments addressing the immune- mediated and renal inflammation aspects of diabetic nephropathy.
• peptides and compounds derived from IL4RA according to the present disclosure are likely to be able to prevent or halt the predestined inflammatory induced decline in various functions of nephrons of the kidney.
• peptides and compounds derived from IL4RA according to the present disclosure are likely to be able to inhibit renal inflammation which is observed in diabetic nephropathy.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound is a peptide derived from an IL-1 R antagonist protein (IL1 RA), or a variant thereof being at least 70% identical to the peptide derived from I LIRA.
• IL1 RA IL-1 R antagonist protein
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound is a peptide derived from an IL-1 R antagonist protein (IL1 RA), or a variant thereof being at least 70% identical to the peptide derived from I LIRA.
• IL1 RA IL-1 R antagonist protein
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound is a peptide derived from an IL-1 R antagonist protein (IL1 RA), or a variant thereof being at least 70% identical to the peptide derived from IL1RA.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a multimeric compound for use in the treatment of diabetic nephropathy, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns use of a multimeric compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• SGRKSSKMQA amino acid sequence of SEQ ID NO:1
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• SGRKSSKMQA amino acid sequence of SEQ ID NO:1
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• SGRKSSKMQA amino acid sequence of SEQ ID NO:1
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein the multimeric compound consists of i) two or more peptides wherein each of the two or more peptides consists of 10 to 14 consecutive amino acid residues derived from I LIRA, each peptide: a. consisting of the amino acid sequence of SEQ ID NO:1 and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues; or b.
• the present disclosure concerns a multimeric compound for use in the treatment of diabetic nephropathy, wherein the multimeric compound consists of i) two or more peptides wherein each of the two or more peptides consists of 10 to 14 consecutive amino acid residues derived from I LIRA, each peptide: a. consisting of the amino acid sequence of SEQ ID NO:1 and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues; or b. consisting of a variant of SEQ ID NO: 1 , the variant comprising one conservative amino acid substitution, and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues, and ii) optionally one or more linker groups.
• the present disclosure concerns use of a multimeric compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the multimeric compound consists of i) two or more peptides wherein each of the two or more peptides consists of 10 to 14 consecutive amino acid residues derived from I LIRA, each peptide: a. consisting of the amino acid sequence of SEQ ID NO:1 and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues; or b. consisting of a variant of SEQ ID NO:1, the variant comprising one conservative amino acid substitution, and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues, and ii) optionally one or more linker groups.
• Figure 1 shows urinary albumin corrected for creatinine (ACR) in a urine sample after treatment with vehicle, 3 mg/kg SER140, 10 mg/kg SER140 and 20 mg/kg SER140 of Renin AAV Uni-nephrectomized db/db (Renin AAV UNx) mice for a period of 77 days.
• Figure 1 shows the medians of the different groups. See Example 1.
• Figure 2 shows urinary KIM-1 corrected for creatinine (KIM-1/CR) in a urine sample after treatment with 3 mg/kg SER140, 10 mg/kg SER140 and 20mg/kg SER140 of Renin AAV Uni-nephrectomized (Renin AAV UNx) mice for a period of 77 days.
• Figure 2 shows the means of the different groups. See Example 1.
• ACR Albumin corrected for creatinine DKD: Diabetic kidney disease.
• IL1RA or IL1 Ra IL-1 receptor antagonist protein, may also be denoted IL-1 receptor antagonist herein.
• IL-1 Interleukin 1.
• IL1R1 or IL1 R1 IL1 receptor type 1.
• KIM-1 Kidney Injury Molecule-1
• KIM-1/CR KIM-1 corrected for creatinine
• ReninAAV UNx mice Renin AAV uninephrectomized db/db mice
• Diabetic nephropathy and “diabetic kidney disease (DKD)” are used interchangeably to refer to the same disease.
• Diabetic nephropathy is a type of progressive kidney disease that may occur in individuals with diabetes mellitus. It affects individuals with type 1 and type 2 diabetes, and risk increases with the duration of the disease and other risk factors like high blood pressure and a family history of kidney disease.
• the term “individual” refers to vertebrates, particular members of the mammalian species, preferably primates including humans. As used herein, ‘subject’ and ‘individual’ may be used interchangeably.
• an “individual in need thereof” refers to an individual who may benefit from the present disclosure.
• the individual in need thereof is a diseased individual.
• the individual in need thereof is a diseased individual, in particular an individual with diabetes mellitus, type 1 or 2.
• Co-administering or “co-administration” of compounds of the present disclosure and other medicaments, as used herein, refers to the administration of one or more compounds of the present disclosure and another medicament within a certain time period.
• the time period might be less than 72 hours, such as 48 hours, for example less than 24 hours, such as less than 12 hours, for example less than 6 hours, such as less than 3 hours.
• these terms also mean that the compound and a therapeutic composition can be administered together.
• Co-administration may be simultaneous, separately or sequentially.
• an “effective amount” of a compound can be administered in one administration, or through multiple administrations of an amount that total an effective amount, for instance within a 24-hour period. It can be determined using standard clinical procedures for determining appropriate amounts and timing of administration. It is understood that the "effective amount” can be the result of empirical and/or individualized (case-by-case) determination on the part of the treating health care professional and/or individual.
• Sequence identity is the number of amino acid residues which match exactly between two different sequences to be compared. If a variant is 90% identical to a sequence having ten amino acid residues, the variant can differ from the sequence by one amino acid substitution.
• beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e. , not worsening) condition, delay or slowing of progression or worsening of condition/symptoms, amelioration or palliation of the condition or symptoms, and remission (whether partial or total), whether detectable or undetectable.
• a “treatment effect” or “therapeutic effect” is manifested if there is a change in the condition being treated, as measured by the criteria constituting the definition of the terms “treating” and “treatment.”
• There is a “change” in the condition being treated if there is at least 5% improvement, alternatively 10% improvement, alternatively at least 25%, alternatively at least 50%, such as at least 75%, alternatively at least 100% improvement.
• the change can be based on improvements in the severity of the treated condition in an individual, or on a difference in the frequency of improved conditions in populations of individuals with and without treatment with the compound, or with the compound in combination with a pharmaceutical composition of the present disclosure.
• a treatment according to the disclosure may be prophylactic, ameliorating or curative.
• variant means that the peptide sequence may be modified, for example by substitution of one or more of the amino acid residues. Both L-amino acids and D- amino acids may be used. Other modification may comprise derivatives such as esters, sugars, etc., for example methyl and acetyl esters, as well as polyethylene glycol modifications.
• an amine group of the peptide may be converted to amides, wherein the acid part of the amide is a fatty acid.
• Conservative substitutions may be introduced in any position of a preferred predetermined peptide for use according to the disclosure. It may however also be desirable to introduce non-conservative substitutions, particularly, but not limited to, a non-conservative substitution in any one or more positions.
• the peptide sequences of the present disclosure may be prepared by any conventional synthetic methods, recombinant DNA technologies, enzymatic cleavage of full-length proteins which the peptide sequences are derived from, or a combination of said methods.
• Formulations of the compounds of the disclosure can be prepared by techniques known to the person skilled in the art.
• the formulations may contain pharmaceutically acceptable carriers and excipients including microspheres, liposomes, microcapsules, nanoparticles or the like.
• the active compound may be formulated as neutral or salt forms.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound is a peptide derived from an IL-1R antagonist (I LIRA) protein, or a variant thereof being at least 70% identical to the peptide derived from I LIRA.
• I LIRA IL-1R antagonist
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound is a peptide derived from an IL-1R antagonist (IL1RA) protein, or a variant thereof being at least 70% identical to the peptide derived from I LIRA.
• IL1RA IL-1R antagonist
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound is a peptide derived from an IL-1R antagonist protein (IL1RA), or a variant thereof being at least 70% identical to the peptide derived from I LIRA.
• IL1RA IL-1R antagonist protein
• the IL1RA protein has a sequence selected from SEQ ID NOs: 2-5. In one embodiment of the present disclosure, the I LIRA protein has a sequence selected from SEQ ID NOs: 2-4.
• the IL1RA protein is SEQ ID NO:1.
• the IL1RA protein is SEQ ID NO:2.
• the IL1RA protein is SEQ ID NO:3.
• the IL1RA protein is SEQ ID NO:4.
• the compound for use is a peptide consisting of 5 to 35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs: 2-5, or a variant thereof being at least 70% identical to the peptide derived from an I LIRA protein sequence selected from SEQ ID NOs:2-5.
• the peptide consists of at most 30 contiguous amino acid residues, alternatively at most 25 contiguous amino acid residues, alternatively at most 20 contiguous amino acid residues, alternatively at most 15 contiguous amino acid residues, alternatively 10 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5.
• the peptide consists of 5 to 35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5, alternatively 5-30, alternatively 5-25, alternatively 5-20, alternatively 5-15, alternatively 10-20, alternatively 8-18 contiguous amino acid residues derived from an I LIRA protein sequence selected from SEQ ID NOs:2-5.
• the peptide consists of 5 to 35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15, such as 15-20, such as 20-25, such as 25-30, such as 30-35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5.
• the variant is at least 75%, alternatively 80%, alternatively 85%, alternatively 90%, alternatively 95% identical to the peptide derived from an I LIRA protein sequence selected from SEQ ID NOs:2-5.
• the variant is at least 71-80% identical, alternatively 81-85% identical, alternatively 86-90% identical, alternatively 91- 95% identical, such as 96-99% identical to the peptide derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5.
• the compound for use is a peptide consisting of 5 to 35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs: 2-5, or a variant thereof being at least 70% identical to the peptide derived from an I LIRA protein sequence selected from SEQ ID NOs:2-5, wherein said peptide comprises at least the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the compound for use is a peptide consisting of 5 to 20 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs: 2-5, or a variant thereof being at least 70% identical to the peptide derived from an I LIRA protein sequence selected from SEQ ID NOs:2-5, wherein said peptide consist of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues.
• the peptide binds to Interleukin 1 receptor, type 1 (IL1R1), and/or interferes with the binding of IL-1 to IL1R1.
• IL1R1 Interleukin 1 receptor, type 1
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues.
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the peptide binds to IL-1 receptor type 1 (ILR1), and/or interferes with the binding of IL-1 beta to IL1R1.
• ILR1 IL-1 receptor type 1
• the variant of SEQ ID NO:1 comprises one or two amino acid substitutions. In some embodiments of the present disclosure, the variant of SEQ ID NO:1 comprises one amino acid substitution.
• the amino acid substitution(s) is a conservative amino acid substitution.
• the variant of SEQ ID NO:1 comprises one, two or three conservative amino acid substitutions.
• the one or more peptides each consists of i) the amino acid sequence of SEQ ID NO:1, and/or ii) a fragment consisting of 5 or more consecutive amino acid of SEQ ID NO:1, and/or iii) a variant of SEQ ID NO:1 having at least 90% identity to SEQ ID NO: 1 , and/or iv) a variant of SEQ ID NO:1 comprising one amino acid substitution.
• said one or more peptides consist of a fragment consisting of 5 or more consecutive amino acid of SEQ ID NO:1.
• said one or more peptides consist of a fragment consisting of 5, 6, 7, 8 or 9 consecutive amino acid of SEQ ID NO:1.
• said one or more peptides consist of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11,
• said one or more peptides consist of the amino acid sequence of SEQ ID NO:1 , or a variant having 1 amino acid substitution.
• said one or more peptides consist of a variant of SEQ ID NO:1 having 1 amino acid substitution.
• said one or more peptides consist of the amino acid sequence of SEQ I D NO: 1.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a compound to an individual in need thereof, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• SGRKSSKMQA amino acid sequence of SEQ ID NO:1
• the present disclosure concerns a compound for use in the treatment of diabetic nephropathy, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• the present disclosure concerns use of a compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one or two conservative amino acid substitutions.
• the C-terminal amino acid exists as the free carboxylic acid (“-OH”).
• the C-terminal amino acid is an amidated derivative (“-NH _, 2”).
• the N-terminal amino acid comprises a free amino-group (“H-“).
• the N-terminal amino acid is the acetylated derivative (“-Acetyl” or “COCH3”).
• the compound for use is a monomer. In some embodiments of the present disclosure, the compound is a monomer comprising one peptide according to the present disclosure.
• the compound for use is a multimer. In some embodiments of the present disclosure the compound for use is a multimer comprising at least two peptides, such as two or more peptides, according to the present disclosure.
• the compound for use is a multimer.
• the compound for use is a multimer comprising two or more peptides, each peptide consisting of SEQ ID NO: 1 , or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions
• the compound is a dimer, a trimer or a tetramer.
• the compound for use is a dimer comprising two peptides, each peptide consisting of SEQ ID NO: 1 , or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions. In some embodiments of the present disclosure, the compound for use is a tetramer comprising four peptides, each peptide consisting of SEQ ID NO: 1 , or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the compound is a dendrimer.
• the dendrimer is a dimeric dendrimer. In some embodiments, the dendrimer is a tetrameric dendrimer.
• Dendrimers are highly ordered, branched polymeric molecules. Typically, dendrimers are symmetric about the core, and often adopt a spherical three-dimensional morphology.
• the compound for use is a dimeric dendrimer comprising two peptides, each peptide consisting of SEQ ID NO: 1 , or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the compound for use is a tetrameric dendrimer comprising four peptides, each peptide consisting of SEQ ID NO:1, or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the two or more peptides are linked via a peptide bond.
• the two or more peptides are linked via a linker group.
• the linker group is a lysine backbone, such as a lysine backbone comprising one or more lysine residues, such as a plurality of lysine residues.
• the linker group comprises one or more lysine residues.
• the compound for use is a dimeric dendrimer comprising two peptides, each peptide consisting of SEQ ID NO:1, or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and a lysine backbone.
• the compound for use is a tetrameric dendrimer comprising four peptides, each peptide consisting of SEQ ID NO: 1 , or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and a lysine backbone.
• the peptide is a tetrameric dendrimer consisting of four peptides, each peptide consisting of SEQ ID NO: 1 , and a lysine backbone.
• the linker group is a polymer carrier, such as a protein carrier.
• the present disclosure concerns a method for treatment of diabetic nephropathy, the method comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a multimeric compound for use in the treatment of diabetic nephropathy, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns use of a multimeric compound for the manufacture of a medicament for treating diabetic nephropathy, wherein the multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the multimeric compound is dendrimer.
• the multimeric compound is a dimer, trimer or tetramer.
• the multimeric compound is a dimer.
• the multimeric compound is a tetramer.
• the at least two peptides are identical.
• the present disclosure concerns a method for treatment of diabetic nephropathy, said method comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein said multimeric compound comprises four peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• the present disclosure concerns a multimeric compound for use in the treatment of diabetic nephropathy, wherein said multimeric compound comprises four peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• said four peptides are linked via a peptide bond.
• said four peptides are linked via a linker group.
• said linker group is a lysine backbone comprising one or more lysine residues, such as a plurality of lysine residues. In some embodiments of the present disclosure the four peptides are identical.
• each of the four peptides are defined according to the present disclosure.
• the present disclosure concerns a multimeric compound for use in the treatment of diabetic nephropathy, wherein the multimeric compound consists of i) two or more peptides wherein each of the two or more peptides consists of 10 to 14 consecutive amino acid residues derived from I LIRA, each peptide: a. consisting of the amino acid sequence of SEQ ID NO:1 and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues; or b. consisting of a variant of SEQ ID NO: 1 , the variant comprising one conservative amino acid substitution, and optionally additional amino acid residues up to a total length of 11 to 14 amino acid residues, and ii) optionally one or more linker groups.
• the compound is formulated as a pharmaceutical composition.
• the peptide or the compound decreases the urine albumin to creatinine ratio (ACR). In another embodiment, the peptide or the compound decreases the urine albumin to creatinine ratio (ACR) in a dose dependent manner.
• the peptide or the compound decreases the urine level of the biomarker Kidney Injury Molecule-1 (KIM-1). In another embodiment, the peptide or the compound decreases the urine KIM-1 to creatinine ratio (KIM-1/CR). In another embodiment, the urine level of KIM-1 or the urine KIM-1 to creatinine ratio (KIM-1/CR) is decreased in a dose dependent manner.
• KIM-1 biomarker Kidney Injury Molecule-1
• the peptide or the compound decreases the urine KIM-1 to creatinine ratio (KIM-1/CR).
• the urine level of KIM-1 or the urine KIM-1 to creatinine ratio (KIM-1/CR) is decreased in a dose dependent manner.
• the individual has diabetes mellitus, has ACR levels above 30, and/or has increased blood pressure. In another embodiment, the individual has normal blood pressure. In another embodiment, the individual has type I diabetes mellitus or type II diabetes mellitus.
• the individual is treated with antidiabetics. In another embodiment, the individual is treated with antihypertensives.
• the compound is administered in combination with an effective amount of an antidiabetic compound and/or an antihypertensive compound.
• the antihypertensive compound is an ACE inhibitor or angiotensin receptor antagonist.
• the method further comprises a step of administering an effective amount of an antidiabetic compound and/or an antihypertensive compound to the individual.
• the antidiabetic compound and/or the antihypertensive compound is administered simultaneously, before or after administering the compound according to the present disclosure.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a compound to an individual in need thereof, wherein said compound is a peptide derived from an interleukin-1 (IL-1) receptor antagonist (I LIRA) protein, or a variant thereof being at least 70% identical to said peptide derived from an I LIRA protein.
• IL-1 interleukin-1 receptor antagonist
• a compound for use in the treatment of diabetic nephropathy wherein said compound is a peptide derived from an IL-1 receptor antagonist (I LIRA) protein, or a variant thereof being at least 70% identical to said peptide derived from an I LIRA protein.
• I LIRA protein has a sequence selected from SEQ ID NOs: 2-5.
• said peptide consist of 5 to 35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5, such as 5-6, such as 6-7, such as 7-8, such as 8-9, such as 9-10, such as 10-11, such as 11-12, such as 12-13, such as 13-14, such as 14-15, such as 15-20, such as 20-25, such as 25-30, such as 30-35 contiguous amino acid residues derived from an IL1RA protein sequence selected from SEQ ID NOs:2-5.
• said peptide comprises at least the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• said peptide consist of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1 ), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a compound to an individual in need thereof, wherein said compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues. 14.
• a compound for use in the treatment of diabetic nephropathy comprising one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions, and optionally additional amino acid residues up to a total length of 11 to 20 amino acid residues, such as 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acid residues.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a compound to an individual in need thereof, wherein said compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), ora variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• a compound for use in the treatment of diabetic nephropathy wherein said compound comprises one or more peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a compound to an individual in need thereof, wherein said compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one, two or three conservative amino acid substitutions.
• a compound for use in the treatment of diabetic nephropathy wherein said compound is a peptide consisting of the amino acid sequence of SEQ ID NO:1 (SGRKSSKMQA); or a variant of SEQ ID NO:1 comprising one, two or three conservative amino acid substitutions.
• N-terminal amino acid of said peptide comprises a free amino- group (“H-“).
• N-terminal amino acid of said peptide is the acetylated derivative (“- Acetyl” or “COCH3”).
• said compound is a monomer, such as a monomer comprising one peptide.
• linker group is a lysine backbone comprising one or more lysine residues, such as a plurality of lysine residues.
• peptide is a tetrameric dendrimer consisting of four peptides, each peptide consisting of SEQ ID NO: 1 , and a lysine backbone.
• linker group is a polymer carrier, such as a protein carrier.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein said multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• a multimeric compound for use in the treatment of diabetic nephropathy wherein said multimeric compound comprises at least two peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO:1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• SGRKSSKMQA SEQ ID NO:1
• a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• a method for treatment of diabetic nephropathy comprising administering an effective amount of a multimeric compound to an individual in need thereof, wherein said multimeric compound comprises four peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• a multimeric compound for use in the treatment of diabetic nephropathy wherein said multimeric compound comprises four peptides, each peptide consisting of the amino acid sequence SGRKSSKMQA (SEQ ID NO: 1), or a variant of SEQ ID NO:1 comprising one, two or three amino acid substitutions.
• linker group is a lysine backbone comprising one or more lysine residues, such as a plurality of lysine residues.
• Example 1 Effect of IL1RA derived peptide om markers of diabetic nephropathy Materials and methods Animals
• mice 56 female mice (BKS.Cg-Dock7m +/+ Lepradb/db BLKS, 5 weeks of age) were transferred to the Gubra Research animal unit. The animals were group housed until uni-nephrectomies, then single housed. Throughout the habituation and study period the animals were in a light-, temperature- and humidity-controlled room with free access to food and water. All animal experiments were conducted in accordance with Gubra bioethical guidelines, which are fully compliant to internationally accepted principles for the care and use of laboratory animals. Animals were terminated on day 77; blood was taken for later analysis, body weight was recorded, and spot urine was collected.
• SER140 was provided by Phlogo ApS, Copenhagen, Denmark (10mg/ml miliQ water diluted to the different dose formulations).
• SER140 is a dendrimer composed of four monomeric peptides each with the sequence SGRKSSKMQA (SEQ ID NO: 1 ), and coupled to a lysine backbone. Vehicle was miliQ: PBS 1:5.
• mice received an IV injection of Renin adenosin- associated virus (AAV).
• AAV Renin adenosin- associated virus
• the compound as well as the vehicle was administered subcutaneously once daily.
• BG blood glucose
• BIOSEN c-line glucose meter EKF-diagnostics, Germany
• blood for HbA1c analysis was immediately suspended in Hemolyzing Reagent and stored until analysis using autoanalyzer Cobas C-111 with commercial kit (Roche Diagnostics, Germany), plasma urea using commercial kits (Roche Diagnostics).
• Urine samples were stored at minus 80 C until analysis. Urine for measurement of albumin and creatinine were centrifuged at 2000 g for 2 min prior to analysis Urine albumin was measure using a commercial ELISA kit (Bethyl Laboratories, Inc.), according to the manufacturer’s instructions, and urine creatinine was measured using a commercial kit (Roche Diagnostics) on the Cobas c 501 autoanalyzer, according to the manufacturer’s instructions. Urinary KIM-1 was measured using a commercial ELISA kit (R&D Systems), according to the manufacturer’s instructions.
• the tested compound SER140 decreased ACR mg/g (Figure 1) and KIM-1/CR pg/g ( Figure 2) significantly in a dose dependent manner.
• ReninAAV UNx db/db mice is described as one of the best pharmacological models to describe development of diabetic kidney disease (DKD, diabetic nephropathy) and to elucidate compounds influence on the progression of the disease (Nguyen 2019, Sembach 2020). Recent studies indicate that immune system activation and imbalance of immune homeostasis play an important role in the development and progression of diabetic nephropathy.
• IL-1 cytokine consists of three different forms, the 11-1 a, 11-1 b, both IL-1 receptor agonists and IL-1Ra, a natural 11-1 receptor antagonist. All are ligands to the same IL-1R1 receptor. Both 11-1 a and 11-1 b are pro-inflammatory cytokines and are activating downstream while IL-1Ra binds to the IL-1R1 receptor without activating and thus act as a receptor antagonist and modulates a variety of 11-1 related immune and inflammatory responses (Arend 2000, Dinarello 2012, Park 2015). Urine albumin and KIM-1 are both biomarkers of kidney innate inflammation as seen in various autoimmune diseases which involve the kidneys. Human renal biopsies have confirmed the presence of inflammatory cells in both glomeruli, the tubuli and the interstitium at all stages of diabetic nephropathy (Kahn 2019, Calle 2021).
• SER140 is a peptide derived from the human IL-1RA N-terminal domain, which is involved in interactions with IL-1R1. SER140 has been shown to inhibit receptor binding of I L-1 b and therefore reduce the downstream activation of among other the macrophages liberation of TNFa (Klementiev 2014).
• SER140 is shown herein to significantly reduced both urinary albumin, a biomarker of cellular damage of mainly glomerular endothelial and podocyte, and KIM-1, a biomarker of damage of the apical membrane of the proximal renal tubule. These biomarkers are undetectable in urine from patients with normal kidney but detectable is response to ischemic or toxic insults, including diabetes (Alderson 2016, Treacy 2019).
• SEQ ID NO:4 (I LIRA isoform 3)
• Fatima Abid Khan, Syeda Sadia Fatima, Ghulam Mustafa Khan, Sana Shahid: Evaluation of kidney injury molecule-1 as a disease progression biomarker in diabetic nephropathy. Pak J Med Sci. Jul-Aug 2019;35(4):992-996. doi: 10.12669/pjms.35.4.154.
• Giulio Cavalli et al Interleukin 1a: a comprehensive review on the role of I L-1 a in the pathogenesis and treatment of autoimmune and inflammatory diseases. Review Autoimmun Rev. 2021 Mar;20(3).
• Kidney injury molecule-1 expression predicts structural damage and outcome in histological acute tubular injury. Ren Fail. 2019 Nov;41(1):80-87.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Zoology (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (8)

Applications Claiming Priority (1)

Publications (1)

Family

ID=76958978

Family Applications (1)

Country Status (8)

Citations (5)

• 2021
  • 2021-07-13 JP JP2024501194A patent/JP7839260B2/ja active Active
  • 2021-07-13 WO PCT/EP2021/069450 patent/WO2023284947A1/en not_active Ceased
  • 2021-07-13 AU AU2021455992A patent/AU2021455992A1/en active Pending
  • 2021-07-13 CA CA3226176A patent/CA3226176A1/en active Pending
  • 2021-07-13 ES ES21742823T patent/ES3026437T3/es active Active
  • 2021-07-13 EP EP21742823.4A patent/EP4351617B1/en active Active
  • 2021-07-13 US US18/577,588 patent/US20240216464A1/en active Pending
  • 2021-07-13 CN CN202180100484.5A patent/CN117642174A/zh active Pending

Patent Citations (6)

Non-Patent Citations (23)

Also Published As

Similar Documents

Legal Events